Contemporary approaches to treatment of beta-thalassemia intermedia. (Q38013167)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Contemporary approaches to treatment of beta-thalassemia intermedia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ali Taher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Mehran Karimi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

Maria Domenica Cappellini

2 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1

Ali T Taher

1 reference

27 August 2017

Mehran Karimi

3

1 reference

27 August 2017

Maria D Cappellini

4

1 reference

27 August 2017

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

26 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

S24-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

Genetic and biochemical studies of intermediate types of Cooley's anaemia

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Optimal management of β thalassaemia intermedia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Thalassemia intermedia: revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Thalassemia and hypercoagulability

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Cardiac involvement in thalassemia intermedia: a multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Risk factors for pulmonary hypertension in patients with β thalassemia intermedia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Modern treatment of thalassaemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Pulmonary hypertension in beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Risk of infection and death among post-splenectomy patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

The natural history of thalassemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Heart disease in thalassemia intermedia: a review of the underlying pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Overcoming the challenge of patient compliance with iron chelation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Transferrin therapy ameliorates disease in beta-thalassemic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Reversing the hemoglobin switch.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

Deferoxamine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2812%2970008-5

7 January 2021

10.1016/S0268-960X(12)70008-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22631038%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference